A comparison of the cardiac activity of a new antiarrhythmic drug--pipazetate--with quinidine, procainamide, antazoline and diphenylhydantoin.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D000996:Antitussive Agents / Q000494:pharmacology*; D016275:Atrial Function; D003864:Depression, Chemical; D004285:Dogs; D006321:Heart / Q000187:drug effects*; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007093:Imidazoles / Q000494:pharmacology*; D066298:In Vitro Techniques; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D010672:Phenytoin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011342:Procainamide / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011802:Quinidine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D011930:Reaction Time / Q000187:drug effects; D013843:Thiazines / Q000494:pharmacology*
D000889:Anti-Arrhythmia Agents; D000996:Antitussive Agents; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D013843:Thiazines; D010672:Phenytoin; D011802:Quinidine; D011342:Procainamide